Literature DB >> 14643897

Prophylactic and therapeutic treatments with AT 1 and AT 2 receptor antagonists and their effects on changes in the severity of pancreatitis.

Siu Wai Tsang1, Siu Po Ip, Po Sing Leung.   

Abstract

Previous studies showed that a local pancreatic renin-angiotensin system (RAS) was upregulated in experimental acute pancreatitis. RAS inhibition could attenuate pancreatic inflammation and fibrosis, which casts a new light on the role of the pancreatic RAS in pancreatitis. The present study explores the prophylactic and therapeutic potentials, and possible molecular mechanism for the antagonism of angiotensin II receptors on the changes in the severity of pancreatic injury induced by acute pancreatitis. Experimental pancreatitis was induced by an intraperitoneal injection of supra-maximal dose of cerulein. The differential effects of angiotensin II receptors inhibitors losartan and PD123319 on the pancreatic injury were assessed by virtue of using the pancreatic water content, biochemical and histological analyses. Blockade of the AT(1) receptor by losartan at a dose of 200microg/kg could markedly ameliorate the pancreatic injury induced by cerulein, as evidenced by biochemical and histopathological studies. However, blockade of the AT(2) receptor by PD123319 appeared not to provide any beneficial role in cerulein-induced pancreatic injury. Both prophylactic and therapeutic treatments with losartan were effective against cerulein-induced pancreatic injury. The protective action of losartan was linked to an inhibition of NAD(P)H oxidase activity, thus consequential oxidative modification of pancreatic proteins in the pancreas. Inhibition of the AT(1) receptor, but not AT(2) receptor, may play a beneficial role in ameliorating the severity of acute pancreatitis. The differential effects of AT(1) and AT(2) inhibitors on cerulein-induced pancreatic injury might be due to the distinctive mechanism of the AT(1) and AT(2) receptors on the activation of NAD(P)H oxidase. Thus the protective role of AT(1) receptor antagonist, losartan, could be mediated by the inhibition of NAD(P)H oxidase-dependent generation of reactive oxygen species (ROS).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14643897     DOI: 10.1016/s1357-2725(03)00257-7

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  16 in total

Review 1.  The physiology of a local renin-angiotensin system in the pancreas.

Authors:  Po Sing Leung
Journal:  J Physiol       Date:  2007-01-11       Impact factor: 5.182

Review 2.  Potential role of NADPH oxidase in pathogenesis of pancreatitis.

Authors:  Wei-Li Cao; Xiao-Hui Xiang; Kai Chen; Wei Xu; Shi-Hai Xia
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 3.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.

Authors:  Mert Erkan; Simone Hausmann; Christoph W Michalski; Alexander A Fingerle; Martin Dobritz; Jörg Kleeff; Helmut Friess
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-19       Impact factor: 46.802

4.  Angiotensin-converting enzyme gene DD genotype neither increases susceptibility to acute pancreatitis nor influences disease severity.

Authors:  Nevin Oruc; Georgios I Papachristou; Haritha Avula; Adam Slivka; Janette Lamb; David C Whitcomb
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

5.  Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor.

Authors:  K C Sourris; A L Morley; A Koitka; P Samuel; M T Coughlan; S A Penfold; M C Thomas; A Bierhaus; P P Nawroth; H Yamamoto; T J Allen; T Walther; T Hussain; M E Cooper; J M Forbes
Journal:  Diabetologia       Date:  2010-07-15       Impact factor: 10.122

6.  Proteasome inhibitor ameliorates severe acute pancreatitis and associated lung injury of rats.

Authors:  Xi Chen; Shun-Le Li; Tao Wu; Ji-Dong Liu
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

7.  Protective role of angiotensin II type 2 receptor signaling in a mouse model of pancreatic fibrosis.

Authors:  Barbara Ulmasov; Zekuan Xu; Laura H Tetri; Tadashi Inagami; Brent A Neuschwander-Tetri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-11-25       Impact factor: 4.052

8.  Losartan to prevent hyperenzymemia after endoscopic retrograde cholangiopan-creatography: A randomized clinical trial.

Authors:  Tomas Sjöberg Bexelius; John Blomberg; Yun-Xia Lu; Hans-Olof Håkansson; Peter Möller; Carl-Eric Nordgren; Urban Arnelo; Jesper Lagergren; Mats Lindblad
Journal:  World J Gastrointest Endosc       Date:  2012-11-16

9.  No association between losartan use and acute pancreatitis in hypertensive patients.

Authors:  Shih-Wei Lai; Hsien-Feng Lin; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Eur J Hosp Pharm       Date:  2016-05-05

10.  The effect of renin angiotensin system genetic variants in acute pancreatitis.

Authors:  James R A Skipworth; Rian M Nijmeijer; Hjalmar C van Santvoort; Marc G H Besselink; Hans-Ulrich Schulz; Mika Kivimaki; Meena Kumari; Jackie A Cooper; Jay Acharya; Arjun Shankar; Massimo Malago; Steve E Humphries; Steven W M Olde Damink; Hugh E Montgomery
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.